A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Public ClinicalTrials.gov record NCT07003100. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab
Study identification
- NCT ID
- NCT07003100
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Enrollment
- 100 participants
Conditions and interventions
Conditions
- Recurrent Mycosis Fungoides
- Recurrent Sezary Syndrome
- Refractory Mycosis Fungoides
- Refractory Sezary Syndrome
- Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
- Non-Interventional Study Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2024
- Primary completion
- Oct 18, 2026
- Completion
- Oct 18, 2026
- Last update posted
- Sep 8, 2025
2024 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Recruiting |
| Stanford Cancer Institute Palo Alto | Palo Alto | California | 94304 | Not yet recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Not yet recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | Not yet recruiting |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | Not yet recruiting |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Not yet recruiting |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | Not yet recruiting |
| M D Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07003100, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07003100 live on ClinicalTrials.gov.